Lay Description

Dapagliflozin is a novel unique drug recently approved by the FDA for the treatment of type 2 diabetes. In previous studies, we found that in addition to lowering glucose sugar levels in the blood, dapagliflozin increases glucose sugar production by the liver and increases the rate of fat oxidationburning fat in the body. These actions of the drug decrease its effectivnessefficacy in lowering the blood sugar and increase the risk of complications. The aim of of the presentthis study is to understand the mechanism way by whichthat dapagliflozin causes the liver to increase sugar production and fat burning so that these actions, this allows us we can tothen develop methods to prevent them. You are being asked to be a participant in this study because you have type 2 diabetes and your blood sugar is not too high that requires treatment with medications. Or you do not have diabetes and the results of your tests will be used to compare to those with diabetes.

Category

IRB Number

20170214HU

NCT Number

ct.gov registration not required

Open to Enrollment

Yes